Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

BioStock Studio: Cyxone's CEO on the current state and the pipeline

Cyxone

Malmö-based biotech company Cyxone develops new therapies for the treatment of autoimmune diseases, such as rheumatoid arthritis with the phase IIb candidate Rabeximod and multiple sclerosis with drug candidate T20K. Carl-Magnus Högerkorp, recently appointed permanent CEO of Cyxone, visited BioStock's studio to tell us more about the current state and the prospects of the pipeline. 

Watch the interview with Cyxone's (https://www.biostock.se/en/?s=cyxone) CEO Carl-Magnus Högerkorp in the link below.

https://www.biostock.se/en/2022/12/cyxones-ceo-on-the-current-state-and-the-pipeline/

This is a press release from Biostock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team